Kashish Thakur

Thank you for the opportunity. Regarding MedTech business; our MedTech business revenue has grown around 53% YOY, but EBITDA was around 1.6 million. So, what is driving this weak profitability, particularly at like US front and what can we expect sustainable double digit EBITDA margins from when can we expect that?

Next question is on our hospital business; hospital occupancy has improved to 51% but standalone margins were broadly like declined by around 320 bps to 18.4%. So, what was the margin pressure and again can you reinstate your FY27 EBITDA margin guidance?

I recall in previous two quarters we have done few additions in Shalby International in doctors front, so that has been stabilized or we are still adding?